Overview
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study.
This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment.
Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Eligibility
Inclusion Criteria:
- Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready.
- Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase.
Additional eligibility criteria for participants who enter Second Course Phase once they
are enrolled on MK-3475-587:
- Has not received any anticancer systemic treatment since the last dose of
pembrolizumab or a pembrolizumab-based combination in First Course Phase.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Demonstrates adequate organ function.
- Have resolution of any toxic effect(s) of First Course Phase trial treatment with
pembrolizumab or a pembrolizumab-based combination to Grade 1 or less (except
alopecia) before trial treatment in Second Course Phase is started. If participant
received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered
from the toxicity and/or complications of the intervention.
- A female participant is eligible to enroll if she is not pregnant, not breastfeeding,
and ≥1 of the following conditions applies: A woman of childbearing potential (WOCBP)
who agrees to use contraception during the study treatment period and for ≥120 days
(corresponding to time needed to eliminate any study combination treatment(s) plus 30
days (a menstruation cycle) for study treatments with risk of genotoxicity.
Additional eligibility criteria for participants who enter dosing with Lenvatinib:
- Adequately controlled blood pressure (BP) to <150/90 mmHg, with or without
antihypertensive medications.
- For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use a
highly effective contraceptive method while receiving study drug and for 7 days after
the last dose of lenvatinib.
- Is female and not pregnant/breastfeeding and at least one of the following applies
during the study and for ≥4 days after: is not a woman of childbearing potential
(WOCBP), is a WOCBP and uses highly effective contraception (low user dependency
method OR a user dependent hormonal method in combination with a barrier method) or is
a WOCBP who is abstinent from heterosexual intercourse.
Exclusion Criteria:
-There are no exclusion criteria to participate in MK-3475-587.
Participants are excluded from entering Second Course trial treatment once they are
enrolled on MK-3475-587 if any of the following criteria applies:
- Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.
- Has received a live vaccine within 30 days prior to the first dose of Second Course
Phase trial treatment.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second Course
Phase.
- Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with
curative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of the
skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast
cancer that has undergone potentially curative therapy.
- Has known active central nervous system metastases and/or carcinomatous meningitis.
- Has an active autoimmune disease that has required systemic treatment in the past 2
years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a form
of systemic treatment and is allowed.
- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis. Note: Participants that experienced pneumonitis during First Course that
did not meet the criteria for permanent discontinuation are eligible.
- Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has a known history of or is positive for hepatitis B or hepatitis C. For parent
studies where inclusion of participants with hepatitis was permitted, MK-3475-587 will
follow the parent study eligibility criteria for hepatitis.
- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the Second Course Phase eligibility
Visit through 120 days after the last dose of study treatment.
- Has severe cardiovascular disease, i.e., arrhythmias, requiring chronic treatment,
congestive heart failure (New York Heart Association Class III or IV) or symptomatic
ischemic heart disease.
- Has hepatic decompensation (Child-Pugh score >6 [class B and C]).
- Has uncontrolled thyroid dysfunction.
- Has uncontrolled diabetes mellitus.
- Has had an allogeneic tissue/solid organ transplant.
- Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
Additional exclusion criteria for participants who enter dosing with Lenvatinib:
- Has had major surgery within 3 weeks prior to first dose of study intervention(s).
- Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
- Has urine protein ≥1 g/24 hours.
- Has LVEF below the institutional (or local laboratory) normal range, as determined by
multigated acquisition scan (MUGA) or echocardiogram (ECHO).
- Has radiographic evidence of encasement or invasion of a major blood vessel, or of
intratumoral cavitation.
- Prolongation of QT intervals corrected for heart rate using Fridericia's (cube root)
correction (QTcF) interval to >480 ms.
- Has clinically significant cardiovascular disease within 12 months from first dose of
study intervention, including New York Heart Association Class III or IV congestive
heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or
cardiac arrhythmia associated with hemodynamic instability.
- Gastrointestinal malabsorption or any other condition that might affect the absorption
of lenvatinib.
- Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to
the first dose of study drug.
- Has a history of any contraindication or has a severe hypersensitivity to any
components of lenvatinib.